Clinical trials: Uveitis, Intermediate
Uveitis, Intermediate Uveitis
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- NCT01789320
- Testing
- triamcinolone acetonide (Triesence®)
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Clearside Biomedical, Inc.
Intermediate Uveitis, Posterior Uveitis
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.
- Trial name
- NCT00333814
- Testing
- Dexamethasone
- Where
- 18 sites in United States, Australia and 16 more
- Volunteers
- 229 people
- Sponsor
- Allergan
Uveitis
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
The purpose of the extension study was to provide patients completing the 28-week core study (NCT01095250) with an opportunity to receive an additional 22 weeks of continuous treatment.
- Trial name
- INSURE (NCT01103024)
- Testing
- AIN457
- Where
- 11 sites in United States, Canada and 3 more
- Sponsor
- Novartis
Uveitis, Uveitis, Posterior
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Intermediate
- Trial name
- NCT05070728
- Testing
- FAI Insert
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Uveitis
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.
- Trial name
- NCT02916017
- Where
- 39 sites in Japan
- Volunteers
- 259 people
- Sponsor
- AbbVie
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
- Trial name
- ENDURE (NCT01090310)
- Testing
- AIN457
- Where
- 35 sites in United States, Brazil and 6 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis
Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
Primary Objective: To evaluate the efficacy of sarilumab at Week 16 in participants with non-infectious uveitis (NIU). Secondary Objectives: To evaluate the change in best corrected visual acuity (BCVA).
- Trial name
- SARILNIUSATURN (NCT01900431)
- Testing
- Sarilumab, Prednisone, Methotrexate
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 58 people
- Sponsor
- Sanofi
Uveitis
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
This study aims at evaluating real life effectiveness of originator adalimumab (Humira®) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including…
- Trial name
- HOPE (NCT03155243)
- Where
- 28 sites in Austria, Colombia and 10 more
- Volunteers
- 155 people
- Sponsor
- AbbVie
Uveitis
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.
- Trial name
- EYEGUARD™-E (NCT02258854)
- Testing
- Dose 2 gevokizumab
- Where
- 33 sites in United States
- Volunteers
- 69 people
- Sponsor
- XOMA (US) LLC
Uveitis
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
- Trial name
- INSURE (NCT01095250)
- Testing
- AIN457
- Where
- 36 sites in United States, Canada and 11 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Behcet Disease
Phase III Study in Refractory Behcet's Disease
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study…
- Trial name
- SHIELD (NCT00995709)
- Testing
- AIN457
- Where
- 49 sites in United States, Egypt and 15 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Non-infectious Uveitis
Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis
Primary objective: safety and tolerability Secondary objectives: additional indicators of long term safety and indicators of clinical activity Exploratory objectives: to characterize EYS606 biodistribution, immunogenicity and…
- Trial name
- NCT03308045
- Testing
- pEYS606
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Eyevensys
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
- Trial name
- NEPTUNE (NCT05523765)
- Testing
- Brepocitinib
- Where
- 15 sites in United States
- Volunteers
- 26 people
- Sponsor
- Priovant Therapeutics, Inc.
Open Angle Glaucoma, Angle Closure Glaucoma
Oculusgen (Ologen) Glaucoma MMC Control in Estonia
To compare the safety and effectiveness between ologen collagen matrix and mitomycin-C (MMC) in glaucoma surgery. The ologen collagen matrix implantation procedure is same as traditional trabeculectomy except implant the ologen…
- Conditions
- Open Angle Glaucoma, Angle Closure Glaucoma, Uveitis Glaucoma, Young Age Glaucoma
- Trial name
- NCT00524758
- Testing
- ologen (oculusgen) collagen matrix, MMC in Trabeculectomy
- Where
- Estonia
- Volunteers
- 20 people
- Sponsor
- Pro Top & Mediking Company Limited
Uveitis
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
- Trial name
- Visual II (NCT01124838)
- Testing
- Adalimumab, Prednisone
- Volunteers
- 261 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Uveitis
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.
- Trial name
- EYEGUARD™-C (NCT01747538)
- Testing
- Dose 1 gevokizumab, Dose 2 gevokizumab
- Where
- 115 sites in United States, Argentina and 20 more
- Volunteers
- 281 people
- Sponsor
- XOMA (US) LLC
Macular Edema, Radiation Retinopathy
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.
- Conditions
- Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane
- Trial name
- NCT04120311
- Testing
- Episcleral Dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Targeted Therapy Technologies, LLC
Uveitis, Posterior Uveitis
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
The purpose of this study is to assess the safety, tolerability, and efficacy of AEB071 as a therapy for uveitis. Vision improvement and reduction in the swelling of retina will be measured for the assessment of efficacy.
- Conditions
- Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- NCT00615693
- Testing
- AEB071
- Where
- 13 sites in United States
- Volunteers
- 13 people
- Sponsor
- Novartis
Uveitis
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
A study comparing the safety and efficacy of adalimumab compared with placebo in patients with active uveitis.
- Trial name
- VISUAL l (NCT01138657)
- Testing
- Adalimumab, Prednisone
- Volunteers
- 239 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Non-infectious Intermediate Posterior- or Pan-uveitis
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
Non-infectious intermediate-, posterior- and pan-uveitis (NIIPPU) are sight threatening diseases with a high patient burden and negative impact on quality of life.
- Trial name
- NCT05414201
- Testing
- Adalimumab
- Where
- 7 sites in China
- Volunteers
- 87 people
- Sponsor
- AbbVie